Effective treatment for dermatophytoses of the foot: Effect on restoration of depressed cell-mediated immunity

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 8, 2007, Pages 1013-1018

  Schmid wendtner, Monika Hildegard ^a   Korting, H C ^b  

^a UNIVERSITY OF BONN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cell mediated immunity; Chronic infection; Delayed type hypersensitivity; Dermatophytoses; Terbinafine; Treatment

Indexed keywords

ANTIFUNGAL AGENT; BIFONAZOLE; CLOTRIMAZOLE; COTRIMOXAZOLE; FLUCONAZOLE; FUNGUS ANTIBODY; FUNGUS ANTIGEN; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; OXICONAZOLE; PLACEBO; TERBINAFINE;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATOMYCOSIS; DERMATOPHYTE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FOOT DISEASE; FUNGAL STRAIN; GASTROINTESTINAL TOXICITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFECTION RISK; LIVER TOXICITY; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REINFECTION; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TASTE DISORDER; TINEA PEDIS; TREATMENT DURATION;

ANIMALS; ANTIFUNGAL AGENTS; FLUCONAZOLE; FOOT DERMATOSES; HUMANS; IMMUNITY, CELLULAR; ITRACONAZOLE; KETOCONAZOLE; MYCOSES; NAPHTHALENES;

EID: 34548154252     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02364.x     Document Type: Review

References (43)

1. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-288.
2. Burzykowski T, Molenberghs G, Abeck D et al. High prevalence of foot diseases in Europe: Results of the Achilles Project. Mycoses 2003; 46: 496-505.
3. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-89.
4. Katsambas A, Abeck D, Haneke E et al. The effects of foot disease on quality of life: Results of the Achilles Project. J Eur Acad Dermatol Venereol 2005; 19: 191-195.
5. Midgley G, Moore MK, Cook JC, Phan QG. Mycology of nail disorders. J Am Acad Dermatol 1994; 31 (Sup pl.): 68-74.
6. Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: Mycological findings from the Multicenter Onychomycosis Study of Terbinafine. Arch Dermatol 1997; 133: 1317-1318.
7. Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology 1997; 194 Suppl 1: 40-42.
8. Roberts DT. The clinical efficacy of terbinafine in the treatment of fungal infections of the nails. Rev Contemp Pharmacother 1997; 8: 299-312.
9. Sanchez Carazo JL, Fuente C, Oliver V et al. Estudio comperativo de terbinafina vs. bifonazol crema al 1% en aplicacion unica diaria en tinea pedis. Actas Dermo Sifiliogr 1994; 85: 388-394.
10. McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycosis. Drugs 1999; 68: 179-202.
11. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: A double-blind, placebo-controlled trial. J Am Acad Dermatol 1990; 23: 804-807.
12. Gupta AK, Ryder JE, Lynch LE, Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: A review of the evidence. J Drugs Dermatol 2005; 4: 302-308.
13. Singurgeirsson B, Olafsson JH, Steinsson JP, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-357.
14. Havu V, HeikkiläH, Kuokkanen K et al. A double-blind, randomized study to compare the efficacy and safety of oral terbinafine with fluoconazole in the treatment of onychomycosis. Br J Dermatol 2000; 142: 97-102.
15. Jansen R, Redekop K, Rutten FFH. Cost-effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: An analysis based on results from the L.I.O.N. Pharmacoeconomics 2001; 19: 401-410.
16. Arrese JE, Piérard-Franchimont C, Piérard GE. A plea to bridge the gap between antifungals and the management of onychomycosis. Am J Clin Dermatol 2001; 2: 281-284.
17. Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: A stubborn clinical problem. Dermatology 2003; 207: 255-260.
18. Shuster S. Onychomycosis: Making sense of the assessment of antifungal drugs. Acta Derm Venereol 1998; 78: 1-4.
19. Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol 2001; 81: 154-155.
20. Pierard GE. Onychomycosis and other superficial fungal infections of the foot in the elderly: A pan-European survey. Dermatology 2001; 202: 220-224.
21. Korting HC, Blecher P, Stallmann D, Hamm G. Dermatophytes on the feet of HIV-infected patients: Frequency, species distribution, localization and antimicrobial susceptibility. Mycoses 1993; 36: 271-274.
22. Herranz P, Garcia J, De Lucas R et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: Treatment with terbinafine. Br J Dermatol 1997; 137: 577-580.
23. Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: A review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatol 2004; 150: 414-420.
24. Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: A multicenter trial. Br J Dermatol 2002; 146: 254-260.
25. Evans EG. Causative agents in onychomycosis and the possibility of treatment resistance: A review. J Am Acad Dermatol 1998; 38: S32-S36.
26. Ahmed AR. Immunology of human dermatophyte infection. Arch Dermatol 1992; 118: 521-525.
27. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259.
28. Calderon RA. Immunoregulation of dermatophytosis. Crit Rev Microbiol 1989; 16: 338-368.
29. Dahl MV. Suppression of immunity and inflammation by products produced by dermatophytes. J Am Acad Dermatol 1993; 28: S19-S23.
30. Jones HE. Immune response and host resistance to human dermatophyte infection. J Am Acad Dermatol 1993; 28: S12-S18.
31. Scavone R, Burger E. Paracoccidioidomycosis: Reduction in fungal load and abrogation of delayed-type hypersensitivity anergy in susceptible inbred mice, submitted to therapy with trimethoprim-sulfamethoxazole. Med Microbiol Immunol 2004; 193: 53-59.
32. Green F, Weber JK, Balish E. The thymus dependency of acquired resistance to Tricopython mentagrophytes dermatophytosis in rats. J Invest Dermatol 1983; 81: 31-38.
33. Moriello KA, DeBoer DJ, Greek J, Kuhl K, Fintelman M. The prevalence of immediate and delayed type hypersensitivity reactions to Microsporum canis antigens in cats. J Feline Med Surg 2003; 5: 161-166.
34. Blake JS, Dahl MV, Herron MJ, Nelson RD. An immunoinhibitory cell wall glycoprotein (mannan) from Trichophyton rubrum. J Invest Dermatol 1991; 96: 657-661.
35. MacCarthy KG, Blake JS, Johnson KL, Dahl MV, Kalish RS. Human dermatophyte-responsive T-cell lines recognize cross-reactive antigens associated with mannose-rich glycoproteins. Exp Dermatol 1994; 3: 66-71.
36. Elewski BE, El Charif M, Cooper KD, Ghannoum M, Birnbaum JE. Reactivity to trichophytin antigen in patients with onychomycosis: Effect of terbinafine. J Am Acad Dermatol 2002; 46: 371-375.
37. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 2002; 146: 250-253.
38. Molin L, Tarstedt M, Engman C. Oral terbinafine treatment for toenail onychomycosis: Follow-up after 5-6 years. Br J Dermatol 2000; 143: 682-683.
39. Crawford F, Young P, Godfrey C et al. Oral treatments for toenail onychomycosis: A systematic review. Br J Dermatol 2001; 145: 446-452.
40. Korting HC, Kresimon J, Rychlik R. Comparative evaluation of the activity and clinical effectiveness of terbinafine and bifonazole preparations in the treatment of pedal mycosis. Akt Dermatol 2004; 30: 210-217.
41. Korting HC, Rychlik R, Pfeil B. Treatment of interdigital tinea pedis: A systematic review. Dtsch Med Wochenschr 2003; 128: 1819-1824.
42. Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2002; 2: CD001434.
43. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: A case-control study. Dermatology 2004; 209: 301-307.